Plant Name: Rumex dentatus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.836E-08 | 5.922E-04 | AKR1B10, CYP2C19, CYP2C9, CYP3A4, ESR1, HSD11B1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.440E-08 | 5.922E-04 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.410E-07 | 7.676E-04 | CYP3A4, ESR1, ESR2, NR1H4, RORC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.949E-07 | 2.225E-03 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.026E-06 | 4.412E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 4.785E-06 | 5.788E-03 | ESR1, ESR2, NR1H4, PIM1, RORC |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.074E-06 | 6.298E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.074E-06 | 6.298E-03 | GPBAR1, NR1H4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.559E-08 | 4.915E-06 | PTPN1; CSNK2A1; MAPK1; ACP1; PTPRF |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.124E-08 | 4.915E-06 | CYP2C9; ALOX15; CYP3A4; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.961E-06 | 1.362E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.985E-06 | 1.720E-04 | HSD11B1; CYP2C9; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.720E-05 | 4.747E-04 | CYP2C9; ALOX15; MAPK1; CYP2C19 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.835E-05 | 1.572E-03 | PIM1; MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.794E-05 | 1.734E-03 | CYP2C9; ALOX15; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.210E-04 | 2.088E-03 | CYP2C9; CYP3A4; CYP2C19 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.736E-04 | 4.551E-03 | PIM1; MAPK1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.431E-04 | 2.195E-03 | HSD11B1; CYP2C9; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.523E-04 | 4.551E-03 | MAPK1; ESR1; ESR2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.957E-04 | 4.551E-03 | MAPK1; HIF1A; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.671E-04 | 4.959E-03 | PTPN1; NFKB1; PTPRF |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.889E-04 | 5.805E-03 | MAPK1; ESR1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 9.674E-04 | 8.344E-03 | LMNA; MAPK1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.288E-03 | 1.046E-02 | HSD11B1; CYP2C9; AKR1B10; ALOX15; CYP2C19; CYP3A4; HSD17B10 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 9.476E-04 | 8.344E-03 | PTPN1; MAPK1; PTPRF |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.371E-03 | 1.051E-02 | THPO; PIM1; PTPN2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.634E-03 | 1.187E-02 | MAPK1; MAPT; HSD17B10 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.799E-03 | 1.786E-02 | MAPK1; HIF1A; ESR1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.646E-03 | 1.786E-02 | MAPK1; NFKB1; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.182E-03 | 1.817E-02 | MAPK1; HIF1A |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 3.723E-03 | 1.817E-02 | RORC; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.302E-03 | 2.033E-02 | MAPK1; MAPT; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.876E-03 | 1.786E-02 | MAPK1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.836E-03 | 1.817E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.836E-03 | 1.817E-02 | MAPK1; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.977E-03 | 1.786E-02 | HSD11B1; CYP3A4 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.671E-03 | 1.896E-02 | MAPK1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.723E-03 | 1.817E-02 | CYP2C9; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.950E-03 | 1.817E-02 | MAPK1; HIF1A |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.723E-03 | 1.817E-02 | MAPK1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.070E-03 | 2.784E-02 | PIM1; MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.671E-03 | 1.896E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.671E-03 | 1.896E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.865E-03 | 2.493E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.425E-03 | 1.896E-02 | NR1H4; CYP3A4 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 8.762E-03 | 2.949E-02 | MAPK1; HIF1A |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.269E-03 | 2.975E-02 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 4.924E-03 | 1.942E-02 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 9.615E-03 | 3.015E-02 | MAPK1; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 7.474E-03 | 2.645E-02 | CSNK2A1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.032E-02 | 3.165E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 6.424E-03 | 2.396E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.269E-03 | 2.975E-02 | MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.761E-02 | 4.601E-02 | MAPK1; HIF1A; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.180E-02 | 3.504E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.219E-02 | 3.504E-02 | MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.461E-02 | 4.090E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.219E-02 | 3.504E-02 | MAPK1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.546E-02 | 4.182E-02 | CSNK2A1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.767E-02 | 4.601E-02 | MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.482E-02 | 4.090E-02 | MAPK1; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ELANE |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ELANE |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ELANE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; NFKB1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; NFKB1; ESR1; ESR1; PIM1; CSNK2A1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |